BioCryst Pharmaceuticals | BCRX - Sales Revenues


BioCryst Pharmaceuticals reported $406.56M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Chugai Pharma JPY 321.75B 24.55B Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
DBV Technologies USD 645K 2.13M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 273M 108.3M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026